Edwards Lifesciences CVP Lippis sells $84,196 in stock

Daniel J. Lippis, CVP, JAPAC of Edwards Lifesciences (NYSE:EW), sold 1,020 shares of common stock on November 10, 2025, for a total of $84,196. The sales were executed at a weighted average price of $82.5451, with individual prices ranging from $82.27 to $82.90. The transaction occurred as Edwards Lifesciences trades near its 52-week high of $87.09, with the stock delivering a 26.95% return over the past year. According to InvestingPro analysis, the company appears slightly overvalued relative to its Fair Value.

On the same day, Lippis also exercised employee stock options to acquire 1,020 shares of Edwards Lifesciences common stock at a price of $59.2567, for a total value of $60441. The medical device company, currently valued at $48.8 billion, trades at a P/E ratio of 36.77, reflecting its premium valuation in the healthcare sector.

These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Lippis on July 30, 2025. Following these transactions, Lippis directly owns 22,001.9103 shares of Edwards Lifesciences. He also directly owns 6114.0000 shares of Employee Stock Options.InvestingPro data shows Edwards maintains a "GOOD" financial health score, with management aggressively buying back shares despite the high valuation. For deeper insights and access to the comprehensive Pro Research Report on Edwards Lifesciences, along with 10+ additional ProTips, visit InvestingPro.

In other recent news, Edwards Lifesciences reported robust financial results for the third quarter of 2025, with adjusted earnings per share reaching $0.67, surpassing Wall Street’s forecast of $0.59. The company’s revenue also exceeded expectations, totaling $1.55 billion compared to the anticipated $1.5 billion. This performance reflects a 12.6% year-over-year growth, with significant contributions from the transcatheter aortic valve replacement (TAVR) business, which saw over 10% growth.

Following these results, Bernstein raised its price target for Edwards Lifesciences to $90, maintaining a Market Perform rating. Canaccord Genuity also increased its price target to $84, citing the company’s solid quarterly performance and maintaining a Hold rating. Additionally, Raymond James upgraded the stock rating to Outperform, setting a price target of $96, highlighting fewer reasons to remain neutral on the company. These developments underscore a positive outlook from analysts on Edwards Lifesciences’ recent achievements.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.